May 27, 2025 – SAN DIEGO, California
CRC Oncology is pleased to announce that Dr. Qinhua Cindy Ru, Managing Director, delivered a featured presentation at 2025 DIA China Annual Meeting during the session “Breaking Barriers and Sailing Forward: Opportunities and Challenges for Innovative Drug Globalization,” co-chaired by Dr. Ming Zhou, Boan Biotech CEO, and Ms. Yanwei Liu, Vice President and Head of Regulatory Affairs, Greater China, Takeda Pharmaceuticals.
In her presentation, titled “China’s Innovative Drug Globalization Strategy and Practice - From Collaborative Models to Deal Execution,” Dr. Ru, an experienced business development executive and GxP auditor, emphasized the critical role of a robust Quality Management System (QMS) in enabling cross-border deal execution. “International licensing is no longer just about promising data,” she asserted. “It requires auditability, documentation traceability, and quality integrity across every stage of development.”
During the panel discussion alongside Dr. Jianxin Yang (CEO, CSone Pharmaceuticals), Dr. Tongtong Xue (Founder, Chairman & CEO, Medilink Therapeutics), Dr. John Zhu (Founder, Chairman & CEO, Duality Biotherapeutics), and Mr. Quanhong Yuan (Founder & Managing Partner, Hankong Capital), Dr. Ru further highlighted the importance of embedding business development strategy throughout the entire asset lifecycle, from nonclinical pharmacology to pre-market registration. She also cautioned that while a signed agreement marks a key milestone, clearly defined co-development governance and regulatory responsibilities are essential to ensure smooth post-deal execution.
CRC Oncology remains committed to fostering global partnerships with innovative biopharmaceutical companies and regulatory leaders who share a commitment to quality, transparency, and delivering sustainable value to patients worldwide.
Contact:
CRC Oncology